NASDAQ:CYCN

Cyclerion Therapeuticsinc Stock Insider Trading

Healthcare > Biotechnology

Buy CYCN

*Your capital is at risk

$3.00

-0.0200 (-0.662%)

At Close: Jun 03, 2026

Cyclerion TherapeuticsInc Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -54.26. In total, the insiders bought 5.22M and sold 715.78K CYCN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-54.26
● Buy	5.22M shares
● Sell	715.78K shares
96% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Jun 01, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -54.26. Confidence increased due to high data reliability score of 80. Supported by overwhelming buy-side pressure (96% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Aug 07, 2025 Buy	Stock Option (Right to Buy) A-Award	Chicko Rhonda M. Chief Financial Officer	C-Suite Officer	25 000 Value: $58.9K
Aug 07, 2025 Buy	Stock Option (Right to Buy) A-Award	Chicko Rhonda M. Chief Financial Officer	C-Suite Officer	25 000 Value: $58.9K
Mar 25, 2025 Buy	Common Stock A-Award	Hecht Peter M	Director	181 818 Value: $500.0K
Mar 25, 2025 Buy	Common Stock A-Award	Higgins Michael J Director	Director	9 090 Value: $25.0K
Mar 25, 2025 Buy	Common Stock A-Award	Hecht Peter M	Director	181 818 Value: $500.0K
Mar 25, 2025 Buy	Common Stock A-Award	Higgins Michael J Director	Director	9 090 Value: $25.0K
Nov 21, 2024 Sell	Common Stock, no par value S-Sale	Slate Path Capital Lp 10 Percent Owner	10% Owner	357 880 Value: $555.1K
Nov 21, 2024 Sell	Common Stock, no par value S-Sale	Slate Path Capital Lp 10 Percent Owner	10% Owner	357 880 Value: $555.1K
Aug 05, 2024 Buy	Stock Option (Right to Buy) A-Award	Graul Regina Margaret See Remarks	Officer	55 849 Value: $184.3K
Aug 05, 2024 Buy	Stock Option (Right to Buy) A-Award	Graul Regina Margaret See Remarks	Officer	55 849 Value: $184.3K
Mar 04, 2024 Buy	Common Stock	Chicko Rhonda M. Chief Financial Officer	C-Suite Officer	0 Value: $0
Mar 04, 2024 Buy	Common Stock	Chicko Rhonda M. Chief Financial Officer	C-Suite Officer	0 Value: $0
Jan 01, 2024 Buy	Common Stock A-Award	Hecht Peter M	Director	15 000 Value: $0
Jan 01, 2024 Buy	Common Stock A-Award	Graul Regina Margaret President	CEO / President	50 000 Value: $0
Jan 01, 2024 Buy	Common Stock A-Award	Graul Regina Margaret President	CEO / President	50 000 Value: $0
Jan 01, 2024 Buy	Common Stock A-Award	Hecht Peter M	Director	15 000 Value: $0
Dec 01, 2023 Buy	Common Stock	Graul Regina Margaret President	CEO / President	0 Value: $0
Dec 01, 2023 Buy	Common Stock	Graul Regina Margaret President	CEO / President	0 Value: $0
Dec 01, 2023 Buy	Common Stock	Graul Regina Margaret President	CEO / President	0 Value: $0
Dec 01, 2023 Buy	Common Stock A-Award	Hecht Peter M	Director	15 000 Value: $0
Dec 01, 2023 Buy	Common Stock A-Award	Hecht Peter M	Director	15 000 Value: $0
Dec 01, 2023 Buy	Common Stock	Graul Regina Margaret President	CEO / President	0 Value: $0
Nov 30, 2023 Buy	Common Stock	Katabi Dina Director	Director	0 Value: $0
Nov 30, 2023 Buy	Common Stock	Katabi Dina Director	Director	0 Value: $0
Nov 30, 2023 Buy	Common Stock	Higgins Michael J Director	Director	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CYCLERION THERAPEUTICSINC.

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's dis...

Read Full Profile Here